Study of Belzutifan for Pheochromocytoma or Paraganglioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a pheochromocytoma or paraganglioma through blood or urine tests showing high metanephrine levels (at least 1.5 times the normal limit).
- If you could become pregnant, you must have a negative pregnancy test within 3 days before starting the drug.
- You can give informed consent to participate.
- You do not have severe heart problems, low oxygen levels, or other cancers.
- You are not taking certain medications (like some antifungals, antidepressants, or stomach acid drugs) that could interfere with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is collecting information from people with certain adrenal gland tumors (pheochromocytoma, paraganglioma, or adrenocortical tumor). It aims to learn more about these conditions, which may help improve future care. Both living and deceased patients can be included.
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This study looks at how the immune system responds to rare adrenal or nerve-related tumors (pheochromocytoma and paraganglioma). Researchers want to understand the tumor's environment, which may help improve future treatments.
This trial tests an oral drug called zanzalintinib in people with pheochromocytoma or paraganglioma that has spread or cannot be removed by surgery and has gotten worse. The goal is to see if the drug can slow or stop tumor growth.
Hear when a new Pheochromocytoma/Paraganglioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.